Overview

George Yu is a pragmatic intellectual property trial lawyer, and his practice focuses on patent infringement litigation and counseling. Drawing on a strong background in biochemistry and molecular biology, George is at ease handling matters that involve complex biotechnology and medical technology products. George also has extensive experience in the high-tech and software products fields.

  • Experience

    • Vice President of IP and Litigation for a leading molecular diagnostics company. Managed several litigations, patent office post-grant proceedings, and extensive patent prosecution portfolio, while working closely with other in-house, as well as outside counsel to achieve cost-effective resolutions for the company. Worked closely with senior management to implement IP strategy. Participated in the acquisition of the company.
    • Assistant general counsel for a research leader, developer, manufacturer and worldwide distributor of microarray technology used in analyzing complex genetic information, where he defended the company against claims of patent infringement, including: a matter of patent infringement which ended with a successful summary judgment on non-infringement and was affirmed on appeal; the successful defense of another claim of patent infringement which led to a favorable settlement; and patent litigation work in the District of Delaware, where the opposing party was found to have infringed five of the company's patents and paid the company $95 million as part of a settlement.
    • Currently lead counsel in three patent infringement litigations.
    • Experience in AIA post-grant proceedings on behalf of Petitioners and Patent Owners.
    • Successful trial team member that obtained judgment of obviousness in an ANDA litigation in the District of New Jersey.
    • Successful trial team member in a high-stakes patent matter in the District of Delaware involving recombinant Human Factor VIII resulting in the dismissal of all claims against his clients in an opinion that was recently affirmed by the Court of Appeals for the Federal Circuit.
    • Obtained a pre-answer dismissal for an electronics company in a patent infringement action in the Northern District of California.
    • Defended a semiconductor company in a patent infringement action in the Western District of Washington and helped to negotiate a favorable settlement.
    • Defended an online matchmaking company in a patent infringement action in the Eastern District of Texas and helped to negotiate a favorable settlement.
    • Led the technical and scientific aspects of a high-profile patent infringement case involving monoclonal antibody technology on behalf of one of the world's leading developers of tools, products and services used to screen blood and ensure blood safety in the transfusion industry.
    • Represented a global manufacturing company in a copyright infringement litigation in the Northern District of California and was successful in compelling arbitration in Sweden of a breach of contract claim involving enterprise software.
    • A three-week long bench trial of a trade secret misappropriation matter involving the theft of FDA manuals and cells used to make monoclonal antibodies, in which he represented the plaintiff resulting in a multi-million dollar verdict in favor of his client which was affirmed on appeal.
    • Representing the plaintiff, a nonprofit research institute, in a jury trial involving ownership of patents relating to nucleic acid detection technology.
  • Credentials

    Education

    • University of California - Los Angeles - School of Law, J.D., 1997
      Pacific Basin Law Journal, Member
    • Stanford University, M.S., Biochemistry, 1994
    • Massachusetts Institute of Technology, B.S., Biology, 1988

    Bar Admissions

    • California
    • U.S. Supreme Court
    • U.S. Court of Appeals for the Ninth Circuit
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the Central District of California
    • U.S. District Court for the Eastern District of California
    • U.S. District Court for the Northern District of California
    • U.S. District Court for the Southern District of California
    • U.S. Patent and Trademark Office

      Clerkships

      • Judicial Extern — Honorable Gary L. Taylor, U.S. District Court, Central District of California 

      Professional Memberships

      • Law360 Life Sciences Editorial Advisory Board, Member
      • American Bar Association
      • American Intellectual Property Law Association, Biotech Litigation Subcommittee, Co-chair
      • Regulatory Affairs Professionals Society
    • Insights

      TITLE
      News Release

      George Yu Named to Law360 2019 Life Sciences Advisory Board

      Partner George Yu has been selected for the Law360 2019 Life Sciences Editorial Advisory Board. According to Law360, the purpose of the nine-lawyer board is to gain insight from experts in the field on how best to shape future coverage.

      News Release

      Seven Attorneys Named Northern California Super Lawyers and Rising Stars

      Schiff Hardin is pleased to announce that seven attorneys have been named to the 2018 Northern California Super Lawyers and Rising Stars lists.

      Article
      Alert

      Pharma Giants in Antitrust Pricing Lawsuit over Biosimilars

      Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.

      News Release

      Schiff Hardin Attorneys Named to 2017 Northern California Super Lawyers Lists

      Six Schiff Hardin attorneys have been recognized on the 2017 Northern California Super Lawyers and Rising Stars lists.

      Alert

      Supreme Court Delivers Big Patent-Dance-Limiting Win for Biosimilars

      Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.

      News Release

      Schiff Hardin Elects Nine New Partners Nationwide

      Firm Taps Six in Chicago, Two in San Francisco, One in Ann Arbor for Advancement

      Other Publications

      • “The Future of Stem Cells Faces a Myriad of Obstacles,” (co-author) DDNews (May 2014)
      • “Why Biosimilars Are Being Held Back in the U.S.,” (co-author) Managing Intellectual Property (Dec. 6, 2013)
      • FTC v. Actavis: Will the ‘Rule of Reason’ End Reverse Payment Settlements?” Spicy IP (Jun. 20, 2013)
      • “Forecasting the U.S. High Court’s Gene Patentability Ruling,” (co-author) The Daily Journal (May 8, 2013)
      • Federal Trade Commission v. Actavis, Inc: A Quick Look into Reverse Payments,” Spicy IP (Mar. 22, 2013)
      • “The Gain Act: Providing Additional Market Exclusivity for Antibiotics to Treat Drug-Resistant Infections,” (co-author) Schiff Hardin LLP Intellectual Property Update (Oct. 11, 2012)
      • “The ‘Safe Harbor’ May Be Safer than Expected—Or Maybe Not: The Conflict Created by Momenta Pharmaceuticals v. Amphastar Pharmaceuticals,” (co-author) Bloomberg/BNA Pharmaceutical Law & Industry Report (Aug. 24, 2012)
      • “The Supreme Court's Mayo v. Prometheus Decision: The Implications for Biotechnology,” (co-author) The National Law Review (Mar. 23, 2012)
      • “Justices Weight in on Patents for Personalized Medicine,” (co-author) San Francisco Daily Journal (Apr. 2, 2012)
      • “How the First-To-File Provisions of the America Invests Act Will Affect Biotechnology,” San Francisco Daily Journal (Feb. 1, 2012)
      • “The Scope of Patentable Subject Matter After 'Bilski',” (co-author) National Law Journal (Jan. 31, 2011)
      • “A Framework for Protecting Innovations in Personalized Medicine,” (co-author) Life Sciences Law & Industry (Feb. 27, 2009)
      • “Redefining Obviousness After KSR Decision,” (co-author) Genetic Engineering & Biotechnology News (Oct. 2008)
      • “Case Comment: United States,” Patent World (co-author) (Jun./Jul. 1999)
      • “Injunctive Relief in Patent Litigation,” (co-author) Patent Litigation Handbook Practising Law Institute (Nov. 1996)

      Speeches & Presentations

      • “Recent Developments Relating to Citizen Petitions,” The Momentum International Congress on Paragraph IV Litigation, New York, N.Y. (Sep. 23, 2013)
      • “Hatch-Waxman and BPCIA 101 – A Primer on IP Basics and Regulatory Fundamentals,” American Conference Institute’s Seventh Annual Paragraph IV Disputes, New York, N.Y. (May 6, 2013)
      • “The Patent Litigation Process in the U.S. for Biosimilars,” RAPS Annual Conference, Seattle, Wash. (Oct. 27, 2012)
      • “A Glimpse of the Future – US Biosimilars Litigation Considerations,” Biopractice.com webinar (Dec. 15, 2011)
    • Citizenship

      Pro Bono Activities

      George has volunteered with the Northern District of California Federal Pro Bono Project, recently representing a pro bono client in a trademark infringement action.